Miracell Recruiting for Early-Medium Dementia Stem Cell Clinical Trial
Stem cell company Miracell (CEO Shin Hyun-soon) announced on the 19th that it will conduct a stem cell clinical trial for dementia with the neurosurgery team at Hanyang University Hospital.
The number of young patients with early-onset dementia in their 30s and 40s has been increasing.
Since many patients rely solely on medication, Miracell explained that it and the neurosurgery team at Hanyang University Hospital decided to conduct a clinical trial targeting early-onset dementia patients.
This trial focuses on managing blood vessels, which are the pathways that supply oxygen and nutrients. Since damage to blood vessels can lead to abnormalities in all brain diseases, CD34+, platelets, cytokines, and VGEF growth factors will be injected directly into the blood vessels, transporting them to the brain.
This clinical trial will be conducted under the title “The Effects of Autologous Blood-Derived Stem Cells in Patients with Vascular Dementia (Prospective, Randomized, Controlled Trial).” Accordingly, participants in the clinical trial are currently being recruited for patients with vascular dementia. Vascular dementia is the second most common disease after Alzheimer’s, but currently, there is no clear treatment beyond managing risk factors such as high blood pressure and diabetes. Therefore, this study will selectively isolate cells from the patient’s own blood and inject them safely into the body to assess neurological prognosis, neuroprotective effects, and improvement in dementia symptoms.
The stem cell extraction for this study will be conducted under the leadership of the neurosurgery team at Hanyang University Hospital, using the SMART M-CELL2 and BSC regenerative medicine biosystems developed by Miracell.
CEO Shin Hyun-soon stated, “Smart M-CELL2 and BSC, which have been approved by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, have been approved not only in Korea but also in the EU. Using this device, we selectively extract up to 98% of superior biological molecules and cells, and inject them directly into the body through a safe route, eliminating concerns about side effects.”
Clinical trial subjects are selected after completing a baseline screening. Patients with early-onset dementia aged 40 to 70 who have had vascular dementia for more than three months, have shown minimal improvement despite current medication, and have not seen any improvement in symptoms.